On May 14, Sagent Pharmaceuticals Inc (NASDAQ:SGNT)‘s stock had its “hold” rating restated by stock analysts at Jefferies Group in a report issued on Thursday, American Banking & Market News reports. They currently have a $23.00 price target on the stock. Jefferies Group’s price objective suggests a potential upside of 8.03% from the stock’s previous close. Sagent Pharmaceuticals Inc (NASDAQ:SGNT) net profit margin is 9.70% and weekly performance is 1.77%. On last trading day company shares ended up $22.41. Analysts mean target price for the company is $ 23.71. Sagent Pharmaceuticals Inc (NASDAQ:SGNT) distance from 50-day simple moving average (SMA50) is 3.13%.
On May 28, 2014, Galectin Therapeutics Inc. (Nasdaq:GALT), the leading developer of therapeutics that target galectin proteins to treat fibrosis and cancer, today announced that it has received a notice of allowance from the U.S. Patent and Trademark Office for patent application number 13/998,197 titled “Galactose-Pronged Carbohydrate Compounds for the Treatment of Diabetic Nephropathy and Associated Disorders.” The patent covers both composition claim for and uses of the Company’s carbohydrate-based galectin inhibitor compound GR-MD-02 in patients with diabetic nephropathy, a type of progressive kidney disease that occurs in individuals with diabetes. Diabetic nephropathy is the major cause for chronic renal failure in the United States. Galectin Therapeutics Inc. (NASDAQ:GALT) shares fell -1.52% in last trading session and ended the day on $12.93. Its return on assets is -308.80%. Galectin Therapeutics Inc. (NASDAQ:GALT) quarterly performance is -23.31%.
On may 27, Karyopharm Therapeutics Inc (NASDAQ:KPTI) Director Deepika Pakianathan acquired 114,419 shares of the company’s stock on the open market in a transaction dated Friday, May 23rd. The stock was purchased at an average price of $26.18 per share, with a total value of $2,995,489.42. Karyopharm Therapeutics Inc (NASDAQ:KPTI) shares moved up 0.92% in last trading session and was closed at $26.25, while trading in range of $25.50 -$26.89. Karyopharm Therapeutics Inc (NASDAQ:KPTI) year to date (YTD) performance is 14.53%.
Momenta Pharmaceuticals Inc (NASDAQ:MNTA) President Craig Wheeler unloaded 1,687 shares of Momenta Pharmaceuticals stock on the open market in a transaction dated Thursday, May 15th. The shares were sold at an average price of $11.09, for a total transaction of $18,708.83. Following the completion of the sale, the president now directly owns 377,852 shares of the company’s stock, valued at approximately $4,190,379. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) ended the last trading day at $12.39. Company weekly volatility is calculated as 3.42% and price to cash ratio as 2.92. Momenta Pharmaceuticals, Inc. (NASDAQ:MNTA) showed a positive weekly performance of 2.23%.
On May 27, The Medicines Company (NASDAQ:MDCO) is scheduled to present at the 2014 Jefferies Global Healthcare Conference in New York, NY on June 2nd at 9:00 AM Eastern Time. The Medicines Company (NASDAQ:MDCO) net profit margin is 3.10% and weekly performance is 7.85%. On last trading day company shares ended up $27.90. Analysts mean target price for the company is $33.10. The Medicines Company (NASDAQ:MDCO) distance from 50-day simple moving average (SMA50) is 5.96%.
Leave a Reply